426 related articles for article (PubMed ID: 29378708)
1. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
[TBL] [Abstract][Full Text] [Related]
2. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
[TBL] [Abstract][Full Text] [Related]
3. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
Karaiskos I; Souli M; Giamarellou H
Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
[TBL] [Abstract][Full Text] [Related]
4. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
5. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
[TBL] [Abstract][Full Text] [Related]
7. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Naber KG; Llorens L; Kaniga K; Kotey P; Hedrich D; Redman R
Antimicrob Agents Chemother; 2009 Sep; 53(9):3782-92. PubMed ID: 19581455
[TBL] [Abstract][Full Text] [Related]
8. Plazomicin: A Next-Generation Aminoglycoside.
Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
[TBL] [Abstract][Full Text] [Related]
10. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Klausner HA; Brown P; Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
Curr Med Res Opin; 2007 Nov; 23(11):2637-45. PubMed ID: 17880755
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
[TBL] [Abstract][Full Text] [Related]
12. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
Bilinskaya A; Linder KE; Kuti JL
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM; Sobel JD; Newell P; Armstrong J; Huang X; Stone GG; Yates K; Gasink LB
Clin Infect Dis; 2016 Sep; 63(6):754-762. PubMed ID: 27313268
[TBL] [Abstract][Full Text] [Related]
14. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Redman R; Damiao R; Kotey P; Kaniga K; Davies T; Naber KG
J Chemother; 2010 Dec; 22(6):384-91. PubMed ID: 21303745
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.
Trang M; Seroogy JD; Van Wart SA; Bhavnani SM; Kim A; Gibbons JA; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670433
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
[TBL] [Abstract][Full Text] [Related]
18. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
20. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Kaye KS; Rice LB; Dane AL; Stus V; Sagan O; Fedosiuk E; Das AF; Skarinsky D; Eckburg PB; Ellis-Grosse EJ
Clin Infect Dis; 2019 Nov; 69(12):2045-2056. PubMed ID: 30861061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
